US › Healthcare

Alvotech (ALVO)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$3.84+1.32%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

$105.9M

Revenue YoY

-20.3%

Net profit

$1.0M

Profit YoY

-99.1%

EPS

$-0.09

EPS estimate

$-0.07

Net margin

1.0%

EPS came in at -0.09 against a street estimate of -0.07 — a miss of 28.6%.

Key statistics

Market cap

$1.28B

Forward P/E

7.9

P/B

0.00

Book value

$-0.90

EPS (TTM)

$-0.29

52-week high

$9.25

52-week low

$2.94

50-day MA

$3.55

200-day MA

$4.47

Beta

0.18

Analyst view

Analysts rate Alvotech a buy (2 buy, 2 hold, 0 sell out of 4) with an average price target of $5.75.

Shareholding

Insiders

54.54%

Institutions

5.11%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Alvotech — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.